Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73605938" target="_blank" >RIV/61989592:15110/20:73605938 - isvavai.cz</a>

Alternative codes found

RIV/00098892:_____/20:N0000126

Result on the web

<a href="https://reader.elsevier.com/reader/sd/pii/S0748798320300214?token=4E1EAAD45AB2B94F8E348E43EC8BEAAD773029628FA68B6986DF02BA92B51BCD4C9BC9ECCB24A583C9A2FB40000AEB74" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S0748798320300214?token=4E1EAAD45AB2B94F8E348E43EC8BEAAD773029628FA68B6986DF02BA92B51BCD4C9BC9ECCB24A583C9A2FB40000AEB74</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejso.2020.01.020" target="_blank" >10.1016/j.ejso.2020.01.020</a>

Result language

angličtina

Original language name

Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study.

Original language description

Introduction: This study aimed to evaluate the costs of CRS and HIPEC and treatment of the related postoperative complications in the public healthcare system. We also aimed to identify the risk factors that increase the cost of CRS and HIPEC. Materials and methods: We retrospectively evaluated 80 patients who underwent CRS and HIPEC between February 2016 and November 2018 in the Department of Surgery, University Hospital of Olomouc, Czech Republic. Intraoperative factors and postoperative complications were assessed. The treatment cost included the surgery, hospital stay, intensive care unit (ICU) admission, pharmaceutical charges including medication, hospital supplies, pathology, imaging, and allied healthcare services. Results: The postoperative morbidity rate was 50%, and the mortality rate was 2.5%. The mean length of hospitalisation and ICU admission was 15.44 ± 8.43 and 6.15 ± 4.12 for all 80 patients and 10.73 ± 2.93 and 3.73 ± 1.32, respectively, for 40 patients without complications, and 20.15 ± 13.93 and 8.58 ± 6.92, respectively, for 40 patients with complications. The total treatment cost reached V606,358, but the total reimbursement was V262,931; thus, the CRS and HIPEC profit margin was V-343,427. Multivariate analysis showed that blood loss 1.000 ml (p ¼ 0.03) and grade IeV Clavien-Dindo complications (p &lt; 0.001) were independently associated with increased costs. Conclusion: The Czech public health insurance system does not fully compensate for the costs of CRS and HIPEC. Hospital losses remain the main limiting factor for further improving these procedures. Furthermore, treatment costs increase with increasing severity of postoperative complications.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

EJSO

ISSN

0748-7983

e-ISSN

—

Volume of the periodical

46

Issue of the periodical within the volume

4 Part A

Country of publishing house

GB - UNITED KINGDOM

Number of pages

6

Pages from-to

607-612

UT code for WoS article

000527364200018

EID of the result in the Scopus database

2-s2.0-85078096848